Farallon Capital Management’s Audentes Therapeutics, Inc BOLD Stock Holding History

Farallon Capital Management’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,190,000	Closed	-$71.2M	–	133
2019 Q4	$71.2M	Buy	+1,190,000	New	+$44.7M	0.48%	46
2018 Q2	–	Sell	-320,000	Closed	-$9.62M	–	108
2018 Q1	$9.62M	Buy	320,000 +338	+0.1%	+$11.4K	0.07%	72
2017 Q4	$9.99M	Buy	+319,662	New	+$8.78M	0.08%	68

Farallon Capital Management's BOLD Position: Q1 2020 in Review

Farallon Capital Management sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 1,190,000 shares — an estimated $71.2M sold.

Farallon Capital Management first reported a position in BOLD in Q4 2017 and held it in 3 quarters. The position peaked at $71.2M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.

Farallon Capital Management reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
Farallon Capital Management sold 1,190,000 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $71.2M.
Farallon Capital Management first reported a position in Audentes Therapeutics, Inc in Q4 2017 and held it in 3 quarters.
Farallon Capital Management's Audentes Therapeutics, Inc position peaked at $71.2M in Q4 2019.
0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.

Based on Farallon Capital Management's 13F filing for Q1 2020, filed 15 May 2020.